Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Significant Increase in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a large increase in short interest in March. As of March 13th, there was short interest totaling 715,845 shares, an increase of 32.9% from the February 26th total of 538,588 shares. Based on an average daily volume of 127,665 shares, the short-interest ratio is presently 5.6 days. Currently, 74.0% of the company’s stock are sold short.

Sensei Biotherapeutics Stock Up 3.0%

NASDAQ SNSE traded up $0.80 on Friday, reaching $27.68. The company had a trading volume of 114,941 shares, compared to its average volume of 113,616. The company’s fifty day moving average is $21.21 and its 200 day moving average is $13.73. Sensei Biotherapeutics has a 52-week low of $5.00 and a 52-week high of $36.76. The stock has a market capitalization of $34.88 million, a P/E ratio of -1.45 and a beta of -0.12.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on SNSE shares. Wall Street Zen upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Saturday, December 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $30.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.